Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Map My Mole, by Community Dermatology Limited, is a service that offers remote assessments of moles and skin lesions by consultant dermatologists.
Their missions in to bring skin checks to where the patient is, whether at home or in one…
Working in collaboration with partners across health and care, its multi-disciplinary team carries out health technology assessments of health or care technologies that are not a medicine and publishes national guidance on their use in Wales.
Read more here.
Attendees
Sponsors and
Exhibitors
Webinars
Contact us